Scarica l'app Stockscreener
11.18
1.24%
-0.14
Dopo l'orario di chiusura:
11.18
Ars Pharmaceuticals Inc Borsa (SPRY) Ultime notizie
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 4% After Insider Selling - MarketBeat
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal - GlobeNewswire
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock - Investing.com
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of Stock - MarketBeat
Ars Pharmaceuticals CEO sells $1.17 million in stock By Investing.com - Investing.com UK
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpStill a Buy? - MarketBeat
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
ARS Pharmaceuticals to Present at J.P. Morgan's Prestigious Healthcare Conference - StockTitan
Franklin Resources Inc. Trims Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Insider Sell Alert: Justin Chakma Sells 144,605 Shares of ARS Ph - GuruFocus.com
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Brian Dorsey Sells 25,000 Shares - MarketBeat
Justin Chakma Sells 27,272 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5.5%What's Next? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Ars Pharmaceuticals' chief business officer sells $1.77m in stock By Investing.com - Investing.com Australia
Ars Pharmaceuticals' chief business officer sells $1.77m in stock - Investing.com India
Ars Pharmaceuticals COO Brian Dorsey sells $493,858 in stock By Investing.com - Investing.com Australia
Ars Pharmaceuticals COO Brian Dorsey sells $493,858 in stock - Investing.com
ARS Pharmaceuticals 宣布在中国、日本和澳大利亚申请批准 neffy® - GlobeNewswire Inc.
ARS Pharmaceuticals seeks Asia Pacific neffy approvals By Investing.com - Investing.com Canada
Ars Pharmaceuticals' chief business officer sells shares worth $657,625 By Investing.com - Investing.com Nigeria
Ars Pharmaceuticals' chief business officer sells shares worth $657,625 - Investing.com India
ARS Pharmaceuticals seeks Asia Pacific neffy approvals - Investing.com India
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia - The Manila Times
ARS Pharma's Neffy Nasal Spray Seeks Approval in Asia-Pacific After Breakthrough Clinical Results - StockTitan
SPRYARS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES - The Eastern Progress Online
Wexford Capital LP Makes New $3.60 Million Investment in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) Proactive Strategies - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Justin Chakma Sells 50,000 Shares - MarketBeat
Cantor Fitzgerald Analysts Lower Earnings Estimates for SPRY - MarketBeat
Ars Pharmaceuticals' chief business officer sells $2.04 million in stock By Investing.com - Investing.com Canada
Insider Sell: Justin Chakma Sells 90,000 Shares of ARS Pharmaceu - GuruFocus.com
Jacobs Levy Equity Management Inc. Buys 288,021 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Insider Sell: Eric Karas Sells 10,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus.com
Ars Pharmaceuticals director Laura Shawver sells shares for $2.69 million By Investing.com - Investing.com Nigeria
Ars Pharmaceuticals chief commercial officer sells $140,423 in stock - Investing.com India
Ars Pharmaceuticals' chief business officer sells $1.2 million in stock By Investing.com - Investing.com Canada
Ars Pharmaceuticals director Laura Shawver sells shares for $2.69 million - Investing.com
Ars Pharmaceuticals' chief business officer sells $1.2 million in stock - Investing.com
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost - The Manila Times
ARS Pharmaceuticals Launches Free Nasal Spray Allergy Program for K-12 Schools, Tackles Critical Safety Need - StockTitan
Miura Global Management LLC Takes $3.92 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Neurelis Offs Neffy Stake for $208M - San Diego Business Journal
Trade Alert: Chief Business Officer & Secretary Of ARS Pharmaceuticals Justin Chakma Has Sold Stock - Simply Wall St
Connor Clark & Lunn Investment Management Ltd. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Consensus Target Price from Brokerages - MarketBeat
Insider Sell: Justin Chakma Sells 100,000 Shares of ARS Pharmace - GuruFocus.com
US Growth Stocks With High Insider Ownership For November 2024 - Simply Wall St
ARS Scores Deal Worth Up to $465M - San Diego Business Journal
ARS Pharmaceuticals: Demand Curve Is Key Unknown (NASDAQ:SPRY) - Seeking Alpha
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Misses Revenue Estimates - MSN
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):